Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of chemotherapy plus late-course hypofractionated radiotherapy for limited-stage small cell lung cancer
ChiCTR-ONC-17013640Phase 2Recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of etoposide in small cell lung cancer (SCLC), sponsored by Shanghai Pulmonary Hospital. Primary endpoints: progression-free survival, radiation-induced pulmonary injury and 1 more. Started Dec 2017; status: recruiting.
02
Drugs
etoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR-ONC-17013640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONC-17013640.